CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials

CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials

Even though chemotherapy and immunotherapy emerged to limit continual and unregulated proliferation of cancer cells, currently available therapeutic agents are associated with high toxicity levels and low success rates. Additionally, ongoing multi-targeted therapies are limited only for few carcinog...

Full description

Bibliographic Details
Main Authors: Khalil Khalaf, Krzysztof Janowicz, Marta Dyszkiewicz-Konwińska, Greg Hutchings, Claudia Dompe, Lisa Moncrieff, Maurycy Jankowski, Marta Machnik, Urszula Oleksiewicz, Ievgeniia Kocherova, Jim Petitte, Paul Mozdziak, Jamil A. Shibli, Dariusz Iżycki, Małgorzata Józkowiak, Hanna Piotrowska-Kempisty, Mariusz T. Skowroński, Paweł Antosik, Bartosz Kempisty
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Genes
Subjects:
genome editing
cancer
animal models
experimental oncology
Online Access:https://www.mdpi.com/2073-4425/11/8/921

Internet

https://www.mdpi.com/2073-4425/11/8/921

Similar Items